KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2017 - 2024)

Teva Pharmaceutical Industries (TEVA) has disclosed Asset Writedowns and Impairment for 8 consecutive years, with $679.0 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Asset Writedowns and Impairment rose 259.26% year-over-year to $679.0 million, compared with a TTM value of $1.6 billion through Mar 2024, down 36.57%, and an annual FY2023 reading of $1.1 billion, down 55.95% over the prior year.
  • Asset Writedowns and Impairment was $679.0 million for Q1 2024 at Teva Pharmaceutical Industries, up from $67.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $5.2 billion in Q3 2020 and bottomed at $28.0 million in Q3 2022.
  • Average Asset Writedowns and Impairment over 5 years is $666.8 million, with a median of $227.0 million recorded in 2021.
  • The sharpest move saw Asset Writedowns and Impairment skyrocketed 2433.66% in 2020, then tumbled 99.1% in 2021.
  • Year by year, Asset Writedowns and Impairment stood at $232.0 million in 2020, then dropped by 21.12% to $183.0 million in 2021, then skyrocketed by 689.62% to $1.4 billion in 2022, then crashed by 95.36% to $67.0 million in 2023, then surged by 913.43% to $679.0 million in 2024.
  • Business Quant data shows Asset Writedowns and Impairment for TEVA at $679.0 million in Q1 2024, $67.0 million in Q4 2023, and $48.0 million in Q3 2023.